The drugmaker, which was spun off from Abbott Laboratories (ABT) in Jan., said it earned 82 cents a share ex items in Q3, down 19% from last year and 4 cents over views. Revenue increased 3% to $4.7 bil, also topping forecasts. AbbVie (ABBV) said sales of Humira, which accounts for more than half its revenue, surged 19%. It expects to earn $3.11-$3.13 a share for the full year. Analysts see $3.13. Shares rose 2.9% to 49.30.